Cyclerion Therapeutics (CYCN) Other Accumulated Expenses (2018 - 2019)
Cyclerion Therapeutics (CYCN) posted quarterly Other Accumulated Expenses of $5.6 million for Q1 2019, down 43.3% quarter-over-quarter from $9.8 million in Q4 2018.
Cyclerion Therapeutics (CYCN) Other Accumulated Expenses (2018 - 2019) Analysis & Trends
Cyclerion Therapeutics' Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $5.6 million for Q1 2019.
- In Q1 2019, Other Accumulated Expenses changed N/A year-over-year to $5.6 million; the TTM figure through Mar 2019 stood at $5.6 million (changed N/A YoY), while the FY2018 annual figure was $9.8 million, changed N/A from the prior year.
- Other Accumulated Expenses for Q1 2019 stood at $5.6 million, down from $9.8 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $9.8 million in Q4 2018, with the low at $5.6 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 5.56 Mn |
| Dec 31, 2018 | 9.80 Mn |